SERACH RESULTS FOR" Development "
development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon. 3-Dimensional Expansion : Capacity / Geography / Portfolio Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment. In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value. Thank you for your continued support. Sincerely, John Rim President and CEO, Samsung Biologics
development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic. Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2, John Rim President and CEO, Samsung Biologicsand near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services. 2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years: Capacity Expansion By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion Geography Expansion Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects. Scope Expansion Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.) For the Next Decade 3-Dimensional Expansion - Business Expansion & Portfolio Diversification Source : JP Morgan Healthcare Conference 2021 Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance. In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics
development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress. Bio CMO/CDO/CRO Champing 2030 As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020
development capabilities and future performance in novel drug development, with improved autonomy and agility in business operations. Meanwhile, Samsung Biologics will continue to deliver quality-driven biomanufacturing services, with existing firewalls between Samsung Bioepis, and expand its biopharmaceutical business in its three core drivers: continued capacity enhancement, establishment of growth opportunities in new business areas, such as mRNA and cell and gene therapies, and global expansion. Samsung Biologics is currently building Plant 4, which will break its own record of holding the world’s largest biomanufacturing capacity, and will begin construction this year of a new facility, Plant 5, which will offer multi-modal product services. In addition, the company is in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site. Through these milestones, Samsung Biologics continues to deliver on its commitment to its clients and shareholders as a top-tier biopharmaceutical company, while advancing the industry with unparalleled innovation, quality, and client satisfaction.
development and manufacturing
organization, today announced strong financial results for the fourth quarter and
record-high earnings for the fiscal year of 2021.
John Rim, CEO of Samsung Biologics, stated, “With a steep
increase in demand for medicines due to the prolonged COVID-19 pandemic, there
was a great need for CDMO capabilities around the world to ensure a reliable
supply of high-quality biological products. By successfully managing all
potential impact from the pandemic with strong business continuity and
operational excellence, Samsung Biologics achieved solid growth and increased
sales in an extraordinary year and made meaningful progress in building
momentum around our long-term business and capacity. Our fourth-quarter
financial performance demonstrates our ability to execute a robust and
resilient approach to maintaining business continuity while adapting at every
level to the needs of our clients and partners. Our concerted efforts have
enabled us to achieve our financial targets and lay a foundation to deliver
future growth. As we look towards 2022, we remain fully committed to delivering
high-quality, life-saving treatments to our partners and patients around the
FOURTH QUARTER &
FISCAL YEAR 2021 RESULTS
Fourth quarter 2021 revenue was KRW 444.3 billion, an
increase of 18% from KRW 375.3 billion reported for the fourth quarter in the
previous year, attributable to increased utilization of Plants 1 and 3, and
sales activities bringing in new contracts.
Fourth quarter 2021 operating profit was KRW 128.8 billion,
39% higher than the prior-year period leveraging steady sales growth.
Fourth quarter 2021 net profit reached KRW 79.3 billion, a
decrease of KRW 16.9 billion from KRW 96.2 billion in the fourth quarter a year
ago, and fourth quarter 2021 operating margin was 29% due to increased
utilization across all plants and improved product mix.
Samsung Biologics demonstrated strong operational
excellence and business agility in 2021 with Plants 1, 2, and 3 in stable
operations, and laid a strong mRNA business foundation through signing strategic
partnership agreements with Moderna for fill and finish and Greenlight
Biosciences for the manufacturing of mRNA vaccines. Samsung Biologics also
launched its newest CDO process platform, S-CellerateTM, which
offers an expedited process for the development and commercialization of monoclonal
FISCAL YEAR 2022
파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.
뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in EffectFebruary 25, 2020
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drugmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Agreement for Novel Targetmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Targetmore